Vimelea Therapeutics

What Vimelea Therapeutics does

Vimelea Therapeutics, Inc. is a privately held, pre-clinical stage drug development company headquartered at 9711 Washingtonian Boulevard, Suite 550, Gaithersburg, Maryland. The company was founded by Dr. Darius M. Walker and operates with a small team of 1-10 employees, supplemented by five business advisors and two scientific advisors (Prof. William Harnett and Prof. Colin Suckling). Vimelea is developing a proprietary platform of therapeutic small molecules derived from a natural immunomodulating system, with its primary therapeutic target being cutaneous lupus erythematosus (CLE), a chronic autoimmune inflammatory skin condition.

The company's core technology is a library of small molecule compounds with three distinguishing technical features: (1) dual modulation of both myeloid and lymphoid immune cells, both implicated in CLE pathology; (2) tissue-selective activity designed to function only in unbalanced immune tissue, mitigating toxicity in healthy tissue; and (3) chemical structures amenable to efficient manufacturing. The company positions the platform as applicable beyond CLE to a broader set of autoimmune and chronic inflammatory diseases, though these are expansion indications rather than active programs at this stage.

Vimelea does not yet have commercialized products and generates no revenue. Its implicit business model follows the standard pre-clinical biotech trajectory: advance compounds through IND-enabling studies and clinical trials, with future revenue potentially derived from out-licensing, co-development partnerships with larger pharmaceutical companies, or independent commercialization. No funding rounds, institutional investors, partnerships, or licensing agreements are disclosed in the available source material, and the company does not currently have an active public-facing product marketing or distribution channel.

Name

Vimelea Therapeutics

Legal name

Vimelea Therapeutics, Inc.

Website

https://vimelea-thera.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Biopharmaceutical R&D

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Small molecule therapeutics
• Autoimmune disease drugs
• Inflammatory disease therapy
• Cutaneous lupus treatment
• Preclinical drug development

Headquarters

HQ city

Gaithersburg

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Vimelea Therapeutics is a pre-clinical biopharmaceutical company developing novel therapeutic small molecules for inflammatory diseases, with a primary focus on cutaneous lupus erythematosus (CLE) and broader applications in autoimmune and chronic inflammatory conditions. The company is building a pipeline of small-molecule drug candidates derived from a nature-inspired immunomodulating system, designed to address unmet medical needs in CLE where there are no FDA-approved treatments.

Product overview

Vimelea Therapeutics is a pre-clinical stage drug development company developing a unified platform of therapeutic small molecules derived from an immunomodulating system in nature. The company's library of small molecule compounds is designed to treat cutaneous lupus erythematosus (CLE) as the primary therapeutic target, with expansion potential to other autoimmune and chronic inflammatory diseases. The lead compounds modulate both myeloid and lymphoid immune cells and are designed to be active only in unbalanced immune tissue, thereby mitigating toxicity in healthy tissue.

Differentiator

Problem solved

Functional benefit

Products and services

• Therapeutic Small Molecule Drug Candidates for Cutaneous Lupus Erythematosus
• Therapeutic Small Molecule Candidates for Autoimmune and Chronic Inflammatory Diseases

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Recent moves3 records

Expansion highlights3 records

Direct peers

• Aclaris Therapeutics: Clinical-stage company developing small-molecule therapeutics for immuno-inflammatory and dermatologic diseases — directly comparable therapeutic area and small-molecule modality to Vimelea.
• Landos Biopharma: Was a clinical-stage small-molecule developer for autoimmune diseases such as ulcerative colitis — comparable small-molecule inflammatory disease focus at similar early stage.
• IFM Therapeutics: Was a small-molecule drug developer targeting the innate immune system for inflammatory disease (acquired by Novartis) — comparable modality and inflammation focus.
• ChemoCentryx: Was a small-molecule drug developer focused on autoimmune and inflammatory diseases (avacopan, acquired by Amgen) — relevant precedent for a small-molecule autoimmune company scaling to commercialization.
• Abivax: Clinical-stage biotech developing oral small-molecule therapeutics (e.g., obefazimod) for chronic inflammatory diseases such as ulcerative colitis — comparable platform modality and chronic inflammation indication strategy.
• Dice Therapeutics: Was a clinical-stage small-molecule immunology biotech (acquired by Eli Lilly in 2023) developing oral small molecules for chronic autoimmune diseases — closely comparable to Vimelea's pre-clinical small-molecule autoimmune approach.

Emerging players

• AnaptysBio: Clinical-stage immunology biotech developing therapeutics for inflammatory and autoimmune diseases — comparable therapeutic focus with broader modality (antibodies) and clinical-stage advancement.

Broad incumbents

• GSK: Owns Benlysta, the leading biologic for systemic and cutaneous lupus erythematosus — directly relevant competitor in Vimelea's lead indication and major potential partner/acquirer.
• AbbVie: Major immunology franchise (Humira, Skyrizi, Rinvoq) covering chronic autoimmune and inflammatory diseases — broad incumbent whose commercial footprint Vimelea's future asset would compete against or partner with.
• AstraZeneca: Markets Saphnelo, an IFN-pathway biologic for lupus, and has a deep immunology pipeline — relevant broad incumbent in lupus and broader autoimmune indications targeted by Vimelea.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vimelea-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vimelea Therapeutics